SCHEMBL5543153

SCHEMBL5543153

Cc1nnnn1-c1cccc(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.54
POLB P06746 1/20 0.52
ALDH1A1 P00352 4/20 0.51
LMNA P02545 7/20 0.51
HTT P42858 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
MAPT P10636 4/20 0.49
TP53 P04637 1/20 0.49
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
GAA P10253 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALPG P10696 1/20 0.44
KMT2A Q03164 2/20 0.43
FLT3 P36888 1/20 0.43
S1PR4 O95977 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10053486 0.82 ALDH1A1 (0.70) NOTUMPOLBALDH1A1LMNAHTT
SCHEMBL29715598 0.79 ALDH1A1 (0.50) NOTUMALDH1A1LMNAHTTL3MBTL1
SCHEMBL27610352 0.79 POLB (0.52) NOTUMPOLBALDH1A1LMNAHTT
SCHEMBL3056133 0.79 ALDH1A1 (0.49) NOTUMALDH1A1LMNAHTTL3MBTL1
SCHEMBL18496495 0.79 SMN1; SMN2 (0.65) NOTUMALDH1A1LMNAHTTL3MBTL1
SCHEMBL5540345 0.79 LMNA (0.50) NOTUMPOLBALDH1A1LMNAHTT
SCHEMBL1353845 0.79 ALDH1A1 (0.50) NOTUMALDH1A1LMNAHTTL3MBTL1
SCHEMBL4213757 0.78 ALDH1A1 (0.64) NOTUMPOLBALDH1A1LMNAHTT
SCHEMBL20646850 0.78 TP53 (0.50) NOTUMPOLBALDH1A1LMNAL3MBTL1
SCHEMBL2736476 0.77 LMNA (0.57) POLBALDH1A1LMNAHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885POLB 1637/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.